Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 7/20 | 0.48 |
| ▸ | JAK2 | O60674 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756809 | 0.91 | LRRK2 (0.53) | PDGFRBPDGFRACDK2CCNA2JAK2 | |
| SCHEMBL13756837 | 0.87 | CDK2 (0.56) | PDGFRBPDGFRACDK2CCNA2CDK1 | |
| SCHEMBL13756769 | 0.85 | NUAK1 (0.54) | PDGFRBPDGFRACDK2CCNA2NUAK1 | |
| SCHEMBL13756780 | 0.82 | LRRK2 (0.49) | PDGFRBCDK2CCNA2JAK2 | |
| SCHEMBL4286256 | 0.80 | JAK2 (0.63) | PDGFRBPDGFRACDK2CCNA2CDK1 | |
| SCHEMBL13756838 | 0.79 | GRM5 (0.53) | CDK2CCNA2CDK1SRCJAK2 | |
| SCHEMBL13756773 | 0.79 | EGFR (0.49) | SRCJAK2KMT2A | |
| SCHEMBL13756843 | 0.78 | NUAK1 (0.47) | PDGFRBPDGFRACDK2CCNA2NUAK1 | |
| SCHEMBL13756808 | 0.78 | HTT (0.42) | PDGFRBPDGFRA | |
| SCHEMBL13756839 | 0.77 | JAK2 (0.55) | CDK2CCNA2CDK1JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | PDGFRB 433/4885PDGFRA 353/4885CDK2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.